The purpose of this study is to examine whether Kremezin, Indoxyl sulfate lowering agent improve endothelial dysfunction in stage 3,4 chronic kidney disease patients
Age
20–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with Chronic kidney disease (Stage3 - Stage4)
Patients who are able and willing to understand, sign and date an informed consent document, and authorize access to protected health information
